Elanco Animal Health has announced FDA approval for Zenrelia™, a new once-daily oral JAK inhibitor designed to control pruritus (itching) and atopic dermatitis in dogs. Zenrelia is Elanco’s first entry into the $1.7 billion global canine dermatology market, offering a highly effective and convenient solution for dogs suffering from chronic, acute, or seasonal itch.

In a head-to-head study, Zenrelia was shown to be at least as effective as Apoquel®, the leading JAK inhibitor on the market, with 77% of Zenrelia-treated dogs reaching clinical remission of itch, compared to 53% for Apoquel. This breakthrough product also minimizes the risk of rebound itch, offering visible relief from the first dose with the convenience of consistent once-daily dosing.

“Today marks a historic step for Elanco and for veterinarians seeking more options to treat itchy dogs,” said Jeff Simmons, President and CEO of Elanco Animal Health. “Zenrelia’s superior efficacy and ease of use make it a game-changer for the canine dermatology market, providing a much-needed solution for millions of dogs and their owners.”

Zenrelia is now available for orders in the U.S., with shipping expected in the coming days. For more information, veterinarians can visit Zenreliaforvets.com.